Skip to content

A Integrated Study in Pediatric Patients with Cardiomyopathy

A Pediatric Cardiomyopathy Cohort Study: the Emerging Role of CMR in Clinical Practice

Status
Enrolling by invitation
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06641830
Enrollment
800
Registered
2024-10-15
Start date
2024-09-01
Completion date
2034-09-30
Last updated
2024-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric Cardiomyopathy

Brief summary

This observational study aims to manage children with cardiomyopathy in the long term. It collects baseline data, laboratory test data, and medical imaging data during the hospitalization and follow-up. During their disease progress, participants will undergo cardiovascular magnetic resonance, echocardiography, electrocardiography, laboratory tests, and when hospitalization and follow-up, and the baseline data will be collected in the admission. All the above examination data will be analysed to assess the clinical characteristics, current status of diagnosis and treatment, and the prognostic risk factors for children with cardiomyopathy.

Interventions

None listed

Sponsors

West China Second University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 18 Years
Healthy volunteers
Yes

Inclusion criteria

* Pediatric patients diagnosed with cardiomyopathy.

Exclusion criteria

* a history of cardiovascular disease ( such as congenital heart disease, cardiomyopathy, rheumatic heart disease, valvular disease ). * Mentally abnormal. * Poor compliance. * Heart, kidney and other important organs were seriously incomplete.

Design outcomes

Primary

MeasureTime frameDescription
Major adverse cardiovascular events10 years after the onsetMajor adverse cardiovascular events including cardiac death, transient ischemic attack or stroke, myocardial infarction, arrhythmia, heart failure, severe valvular disease, percutaneous coronary intervention, coronary artery bypass graft, and other cardiovascular surgery.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026